Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jabil Inc (JBL) vs GeneDx Holdings Corp (WGS) Price & Performance

GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Jabil Inc vs GeneDx Holdings Corp — how do they compare? Jabil Inc trades at $366.02 (market cap $37.37B), while GeneDx Holdings Corp trades at $82.2 (market cap $2.44B). The key difference: Jabil Inc is far larger — about 15.3× GeneDx Holdings Corp's market cap, and Jabil Inc pays a 0.09% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

JBLWGS
Market Cap
$37.37B$2.44B
Sector
TechnologyTechnology
52-Week High
$385.50$167.51
52-Week Low
$192.49$34.51
Enterprise Value
$39.90B$2.48B
Dividend Yield
0.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

JBL stock trades at $366.16, up 8.77% in the last session, reflecting strong momentum driven by AI infrastructure demand. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.16 exceeding the $3.10 forecast. Technical indicators show a bullish trend with the stock approaching resistance near $371, while fundamentals reveal solid revenue growth projections from $29.8B in 2025 to $33.6B in 2026.

JBL presents compelling growth potential as an AI infrastructure play with projected revenue exceeding $20B by 2027, though elevated P/E of 44.63 and thin net margins of 2.57% warrant caution. Analyst consensus targets $448.29 (22% upside) with balanced buy/hold ratings. Key risks include execution challenges in scaling AI operations and competitive pressures in electronics manufacturing services.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS